| Literature DB >> 21060024 |
Christoph Schuhmacher1, Stephan Gretschel, Florian Lordick, Peter Reichardt, Werner Hohenberger, Claus F Eisenberger, Cornelie Haag, Murielle E Mauer, Baktiar Hasan, John Welch, Katja Ott, Arnulf Hoelscher, Paul M Schneider, Wolf Bechstein, Hans Wilke, Manfred P Lutz, Bernard Nordlinger, Eric Van Cutsem, Jörg R Siewert, Peter M Schlag.
Abstract
PURPOSE: Patients with locally advanced gastric cancer benefit from combined pre- and postoperative chemotherapy, although fewer than 50% could receive postoperative chemotherapy. We examined the value of purely preoperative chemotherapy in a phase III trial with strict preoperative staging and surgical resection guidelines. PATIENTS AND METHODS: Patients with locally advanced adenocarcinoma of the stomach or esophagogastric junction (AEG II and III) were randomly assigned to preoperative chemotherapy followed by surgery or to surgery alone. To detect with 80% power an improvement in median survival from 17 months with surgery alone to 24 months with neoadjuvant, 282 events were required.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21060024 PMCID: PMC3020693 DOI: 10.1200/JCO.2009.26.6114
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544